Immunic Reports Q3 2026 Results and ENSURE Phase 3 Data Duet
Immunic, Inc. (IMUX) reported Q3 2026 financial results and confirmed that top-line data from its Phase 3 vidofludimus calcium trials in relapsing MS is expected in December 2026 and remains on track.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed